Justwanted to chime in to agree with the GDScoop/Marcus Padley...

Justwanted to chime in to agree with the GDScoop/Marcus Padley advice.

 

In 2011 Australians with a knowledge about biomedical devices were very excited about ELX, who were trialing a revolutionary low intensity laser, totally patented, which was delivering incredible results in treating retinal conditions. The more research you did,the more you got that tingly feeling – we could be dealing with something special.I was working in the sector at the time and realized ELX had the support and buy-in of some incredibly intelligent scientists at the Eye and Ear Hospital in Melbourne. They effectively had a monopoly on treating a common condition at an accessible price point for many elderly patients.

 

Bought a package at36c, then 23c, then 17c. The more exciting and brilliant the company’s announcements were, the more the SP floundered. A lot of self-doubt and exasperation about how the market wasn’t connecting with reality was out there. In addition,medical device approvals and multiple proof of concept studies required A LOT of patience.

 

Three years later (2014),the continued hard work of the company had managed to bring the SP back to my initial buying point – 36c. Noting a good result on my second and third buy packages, and having grown tired of how the market didn’t seem to register the strong traits of the company, I totally sold out. I couldn’t handle the wait –I had deluded myself into thinking that the rest of the buyers out there knew everything I knew, but for some mysterious reason they weren’t interested in ELX.

 

One year later, more great news dropped for the company, but this was the straw that broke the camel’s back. The dam holding back investors ruptured and a flood of investor interest poured down the valley. The stock reached a high of $1.40 – almost eight times what I’d bought the majority of my shares at. But because I’d lacked the patience to deal with the vagaries of the market, I didn’t get to make nearly eight times return on investment.

 

I see a lot of ELX in AGY – strong position for the future, proven subject matter experts guiding the boat and a consistent record of positive news and progress — yet a pessimistic market keeps nagging “Yeah, But What If?”

If anything, AGY is in a stronger position as they don’t need to navigate the hell of biomedical studie sand regulation a manufacturer in the health sector needs to work through.

 

So what have I taken away from it all?

Be disciplined. Set your stop losses and follow them. Realise that life-changing results are delivered in years, not weeks. I look forward to the near future when we can all have a big laugh about the late 2018/early 2019 doldrums

DYOR GLTA